|Systematic (IUPAC) name|
|Legal status||℞-only (US) Investigational|
|Half-life||longer then linezolid|
|Mol. mass||370.338 g/mol|
|(what is this?)|
Tedizolid (formerly torezolid) is an oxazolidinone drug being developed by Cubist Pharmaceuticals following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals) for complicated skin and skin-structure infections (cSSSI), including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
As of July 2012[update], tedizolid had completed one phase III trial, with another one under way.  Both trials compare a six-day regimen of tedizolid 200 mg once-daily against a ten-day regimen of linezolid 600 mg twice-daily. The results of the pivotal phase III trial ESTABLISH 1 were published in February 2013. It met the primary and both secondary endpoints.
Tedizolid has been approved by the FDA on June 20, 2014 for the treatment of methicillin-resistant S. aureus skin infections. It can be taken both orally and given via IV injection.
- "Trius grows as lead antibiotic moves forward". 31 Oct 2011.
- "Trius Completes Enrollment In Phase 2 Clinical Trial Evaluating Torezolid (TR-701) In Patients With Complicated Skin And Skin Structure Infections". Jan 2009.
- PMID 19528279 In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
- PMID 19218276 TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.
- New MRSA treatment
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|